BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 10, 2020

View Archived Issues
2-10-Atlantic-Therapeutics-Innovo.png

FDA gives green light to software that helps in the acquisition of cardiac ultrasound images

Brisbane, Calif.-based Caption Health Inc. received good news from the U.S. FDA, which has given a thumbs up to Caption Guidance. This software aims to assist medical professionals in the acquisition of cardiac ultrasound images and uses artificial intelligence (AI) to provide real-time guidance. Read More
Capitol.png

Budget draft for 2021 eyes NIH cuts along with 10% hit to HHS funding

In a budget proposal sure to spark opposition, the Trump administration has proposed to provide the National Institutes of Health with only $38 billion in fiscal 2021, several billion dollars short of the agency’s funding for the current fiscal year. The proposal also calls for funding of less than $95 billion for the Department of Health and Human Services, a 10% reduction in funding that includes an adjustment for drug pricing proposals and a $5 million cut to FDA monies for the 21st Century Cures Act. Read More
Approval-stamp-blue.png

Carmat wins OK from the FDA for its U.S. clinical feasibility study

PARIS – Carmat SA, from Vélizy-Villacoublay, France, has obtained full FDA approval for its investigational device exemption application (IDE). The company is now able to initiate a U.S. early feasibility study (EFS) of its total artificial heart. “This full approval to initiate a U.S. study confirms the FDA’s confidence in our ability to conduct a feasibility study of the first bio-prosthetic artificial heart in the United States,” Stéphane Piat, CEO of Carmat, told BioWorld. Read More
regulatory-thumbs-up

Irish startup Atlantic goes OTC in the U.S. with wearable treatment for urinary incontinence

The FDA has granted over-the-counter (OTC) clearance to the first noninvasive wearable to treat stress urinary incontinence. The device, known as Innovo, uses electrical stimulation to strengthen pelvic floor muscles and is integrated into fitted shorts. It was already available by physician prescription in the U.S. since an FDA clearance in early 2019. Read More
Science-Credit-University-of-Texas-Southwestern-Medical-Center-2-10

EEG signature can predict response to SSRIs

For depression, and other mental health disorders, the era of precision medicine has yet to arrive. Symptoms are “very poorly reflective of the underlying biology,” Amit Etkin told BioWorld. Depression can manifest through multiple different symptoms that differ both between and within cultures. Read More

Appointments and advancements for Feb. 10, 2020

New hires and promotions in the med-tech industry, including: Coopercompanies, Dysis Medical, Lighthouse Guild. Read More

In the clinic for Feb. 10, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bionano Genomics, Brainsway, Medshape, Tenon Medical. Read More

Other news to note for Feb. 10, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 7D Surgical, Autobio Diagnostics, Cepheid, China Grand Pharmaceutical and Healthcare Holdings, Co-Diagnostics, Elite Medical Technologies, Endonovo Therapeutics, Future Medical Equipment, Medtronic, Mobidiag, Oncosec Medical, Precisionmed, Probo Medical, Sirtex Medical, Seaspine Holdings, Sona Nanotech, Valeritas Holdings, Zealand Pharma. Read More

Regulatory actions for Feb. 10, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Endomag, Nanobiotix, Paragonix Technologies, Rist Neurovascular. Read More

Regulatory front for Feb. 10, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Aethlon Medical. Read More

BioWorld MedTech’s Cardiology Extra for Feb. 10, 2020

Keeping you up to date on recent developments in cardiology, including: Researchers find 'first responder' that triggers plaques; Heart muscle cells alter their energy source during regeneration; More evidence points to rosiglitazone, heart issues. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing